---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Incidence"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Incidence. Topics: Insulinoma, Finland, 1980 to 2010: nationwide incidence in adults; Insulinoma, Western Sweden, 2002 to 2019: regional incidence; Insulinoma, Olmsted County, Minnesota, 1927 to 1986: population-based incidence; Benign and malignant insulinoma, Japan, 2012: incidence from a national inpatient database; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/incidence"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Tumor hyperinsulinism

<a id="topic-2.2.1.2.1-1"></a>

### Insulinoma, Finland, 1980 to 2010: nationwide incidence in adults

> “Retrospective analysis on all adult patients diagnosed with insulinoma in Finland during 1980–2010.”
> “Seventy-nine patients were diagnosed with insulinoma over the research period.”
> “The incidence of insulinoma over the whole research period was 0.6 per million adults per year and increased remarkably during the study period (0.5, 0.4, and 0.9/million/year in the 1980s, 1990s, and 2000s, respectively).”
> “In Poisson regression analysis, the yearly incidence rate ratio was 1.043, and the increase in incidence was statistically significant (p = 0.002).”
> “In the patient record and pathology registry data, the insulinomas were classified as benign in 58 (73%), malignant in 11 (14%), and undetermined in 6 (8%) patients, using the contemporary classifications of PNENs. Distant metastases were documented in 9 (11%) patients.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

<a id="topic-2.2.1.2.1-2"></a>

### Insulinoma, Western Sweden, 2002 to 2019: regional incidence

> “Medical records were reviewed for all patients in the VGR who had received an ICD-10 diagnosis code of a benign (D13.7) and/or a malignant (C25.4) tumor in the endocrine part of the pancreas, of hypoglycemia (E.161), and/or a code of a fasting test (AB011), from 2002-2019.”
> “Forty-two patients with insulinoma were identified, 37 of whom (20 men) were residents in the VGR at the time of diagnosis, giving a mean annual incidence of 1.3 cases per million/year.”
> “Six of the 37 (16%) patients had metastatic insulinoma and 2 patients (5%) had a confirmed multiple endocrine neoplasia type 1 syndrome.”
> “Our results do not support an increasing incidence of insulinoma.”

Source: [Svensson et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9210785/)

<a id="topic-2.2.1.2.1-3"></a>

### Insulinoma, Olmsted County, Minnesota, 1927 to 1986: population-based incidence

> “With use of the complete medical record system at Mayo and the comprehensive epidemiologic data base of residents of Olmsted County, Minnesota, we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.”
> “During the study period, eight cases of insulinoma occurred among residents of Olmsted County; their age and gender distributions were similar to those of the total cohort.”
> “The incidence of insulinoma among residents of Olmsted County increased during the study period to a stable level during the last 2 decades of 4 cases per 1 million person-years.”
> “For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.1.2.1-4"></a>

### Benign and malignant insulinoma, Japan, 2012: incidence from a national inpatient database

> “Using the Japanese Diagnosis Procedure Combination database, we retrospectively identified patients with insulinoma admitted between 2010 and 2018.”
> “We also estimated the incidence of insulinoma using the number of patients with newly diagnosed insulinoma in 2012.”
> “We identified 844 patients with benign insulinoma and 102 patients with malignant insulinoma.”
> “The incidence of insulinoma was estimated to be 3.27 (95% CI, 2.93-3.61) individuals per million Japanese adult population per year.”

Source: [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)

<a id="topic-2.2.1.2.1-5"></a>

### Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey onset incidence

> “The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010.”
> “Non-functioning tumor (NF)-PNETs comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%).”

Source: [Ito et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24499825/)

<a id="topic-2.2.1.2.1-6"></a>

### Malignant insulinoma, United States, 1973 to 2015: SEER registry incidence

> “We identified all patients with malignant insulinoma in the SEER registries from 1973 to 2015.”
> “A total of 121 patients were identified. The crude annual overall incidence was low (range 0.0–0.27 cases per million person years).”
> “The crude annual overall incidence was extremely low, but increased over the study period, from 0.0 to 0.17 cases per million person years. The annual overall incidence reached its peak in 2011 and 2012, at 0.27 cases per million person years. Most recently, the incidence was reported to be 0.17 cases per million person years in 2015.”
> “The largest proportion had localized disease (40%), while 16% had regional disease, 39% distant metastatic disease, and stage was unreported in 5%.”
> “We were unable to compare our observations to benign insulinoma as those cases are not captured by SEER.”

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)

<a id="topic-2.2.1.2.1-7"></a>

### Insulinoma: range of reported incidence across studies (review)

> “Insulinomas are the most common, yet still rare, hormone-producing pancreatic neuroendocrine neoplasms (panNEN) with a reported incidence of 0.7 to 4 cases per million per year”
> “There is an age-specific incidence peak in the fifth decade of life in men and the sixth decade of life in women and the incidence is slightly higher in women than in men”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.2.1-8"></a>

### Non-islet cell tumor hypoglycemia: review estimate of incidence

> “In clinical practice, non‐islet cell tumour hypoglycaemia (NICTH) is considered a rare condition, with an incidence rate of one per million person‐years.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.2.1-9"></a>

### Tumor hyperinsulinism, United States: company estimate of about 3,000 patients per year (September 2026)

> “While we believe the total addressable market may be larger, the immediately addressable incidence market for the combined indications causing tumor HI is estimated to be approximately 3,000 patients in the U.S. alone per year.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.2.1.2.1-10"></a>

### Tumor hyperinsulinism, United States: company estimate of about 4,000 patients per year (November 2026)

> “While we believe the total addressable market may be larger, the immediately addressable incidence market for the combined indications causing tumor HI is estimated to be approximately 4,000 patients in the U.S. alone per year.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
